Although clinical efficacy is a key determinant of the translational potential of a therapeutic, the human impact on patients from translation cannot be achieved unless there is a scalable and robust platform to manufacture the therapeutic in necessary quantities. Industrial processes for biomanufacturing and bioprocessing of therapeutics carry substantially different challenges compared to laboratory or pilot-scale processes. Two contributions in this issue specifically address these challenges. Shukla and colleagues provide a comprehensive review of antibody manufacturing platforms that have been a key enabler for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. Therapeutics.
1 Indeed, the approach of using a natural ligand as a template combined with yeast surface display to rapidly identify potent mutants can be extended to other ligands to develop novel therapeutic antagonists against a broad range of targets. Gorelik and Sidhu offer an informative review on engineered enzyme variants, using ubiquitin as a prototypical example, for discovery of therapeutic candidates. 2 Beyond design of therapeutics, there is a tremendous potential for employing such schemes to validate and discover new functions for targets, and characterize new modulatory sites.
The drug development endeavor has suffered, disproportionately, from promising leads failing in clinical trials due to poor bioavailability and off-target effects. Delivery to in situ targets remains a significant challenge. There is a conscious paradigm shift to combine discovery and delivery efforts early in the drug development process to mitigate failure. Seven contributions in this issue discuss novel approaches, both synthetic and biomimetic, to achieve effective delivery by employing discoveries and innovations in biology, immunology, biochemistry, biophysics, and micro-fabrication. [3] [4] [5] [6] [7] [8] [9] Champion and colleagues describe the biochemical tailoring of nanoparticles with molecular adjuvants to generate specific effector responses against pathogens that offer superior vaccination against infectious diseases. Alongside, they present a systematic scheme for engineering physical properties such as shape, size and stiffness of nanoparticle vectors for tuning the Fc-mediated interactions with macrophages during phagocytosis. 4 Muro and Manthe describe the design of targeted nanocarriers that sequester overexpressed inflammatory agents in disease pathologies providing an attractive approach for design of new therapeutic systems. 5 Swartz and colleagues review the potential for use of virus like particles (VLPs) as highly effective delivery vehicles that overcome the many challenges encountered in targeted delivery of therapeutic cargoes. 6 Desai and colleagues demonstrate inkjet printing of therapeutics in microdevices to circumvent the challenges of low bioavailability, degradation, poor cellular permeability, and low residence time for oral administration. 7 Goto and colleagues describe a simple and easy to use vaccine administration method using a solid-in-oil nanodispersion system incorporating immunomodulatory adjuvants for soliciting specific immune responses via transcutaneous vaccination. 8 And finally, Rege and colleagues review state-of-art approaches in isolation and purification of exosomes, and their potential use in cancer vaccines, drug delivery, and diagnostics.
Collectively, these articles present several exciting and innovative approaches for targeted drug delivery. 
